- Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum As 120+ Key Companies At The Forefront Delveinsight 20/11/2024 01:18 MENAFN (MENAFN- PR Newswire) Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and tissue damage across multiple organ systems, such as the skin, joints, kidneys, heart, and brain. The incidence of autoimmune …
- Triamcinolone, methylprednisolone avoid prednisone’s fracture risk ‘trap’ in lupus 19/11/2024 22:13 Healio News November 19, 2024 1 min read Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio WASHINGTON — Although even low- …
- OMRF receives $412,610 grant to study arthritis 19/11/2024 18:39 The Duncan Banner - Oklahoma The National Institutes of Health has awarded the Oklahoma Medical Research Foundation a $412,610 grant for research aimed at better understanding why some people develop arthritis while others don’t. Using existing human blood samples, physician-scientist …
- DZP Improves Disease Activity and Reduces Corticosteroid Use in SLE 19/11/2024 18:04 Consultant Live Dapirolizumab Pegol (DZP) was superior to placebo in achieving responses in patients with systemic lupus erythematosus (SLE) and permitted corticosteroid tapering.1 These findings, from the phase 3 PHOENYCS GO trial (NCT04294667), were presented by Megan …
- Deepcure’s DC-9476 ameliorates rheumatoid arthritis scores 19/11/2024 17:45 BioWorld
- CAR T for Lupus Takes Center Stage at ACR 2024 19/11/2024 16:14 BioSpace Having proven their worth in several types of blood cancers, autoimmune disease is the next frontier for CAR T therapies. Bristol Myers Squibb, Kyverna Therapeutics, Fate Therapeutics and Cabaletta Bio all presented data on their CAR T candidates for lupus …
- Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III 19/11/2024 16:14 BioSpace Biogen and UCB on Tuesday provided more details regarding their unexpected late-stage victory in the Phase III PHOENYCS GO trial and plotted out a potential regulatory path for their drug candidate dapirolizumab pegol in systemic lupus erythematosus. In …
- Bimekizumab Data From ACR Conference Highlights Sustained Efficacy in Psoriatic Arthritis 19/11/2024 14:29 Dermatology Times UCB recently unveiled new data showcasing the efficacy and safety of bimekizumab-bkzx (Bimzelx) in addressing psoriatic arthritis (PsA), alongside other conditions such as non-radiographic axial spondyloarthritis and ankylosing spondylitis.1 Data was …
- Denosumab increases risk of severe hypocalcemia in women with osteoporosis and chronic kidney disease 19/11/2024 13:48 Physician's Weekly 1. In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment as compared with bisphosphonates among women with osteoporosis in the setting of chronic kidney disease (CKD). 2. The risk of …
- Causal Effects of Rheumatoid Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis on Psoriasis: A Mendelian Randomization Study 19/11/2024 13:24 Dove Medical Press Introduction Psoriasis is a chronic immune-mediated inflammatory characterized by skin erythema, desquamation and with or without joint pain, which is related to many factors such as heredity, environment and auto-immunity.1,2 In recent years, studies have …
